Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015)

Denschlag, Dominik; Thiel, Falk; Ackermann, S.; Harter, P; Juhasz‐Boess, Ingolf; Mallmann, Peter; Strauß, Hans‐Georg; Ulrich, U.; Horn, LC; Schmidt, Dietmar; Vordermark, Dirk; Reichardt, P; Gaß, Paul; Gebhardt, M.; Beckmann, Matthias

doi:10.1055/s-0035-1558288

Cited by 8 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A consensus on the management of metastatic LGESS has not yet been established 12 . Resection of metastatic disease has been reported to offer some benefit 36 . Xu et al reported 36 cases with good outcome after lobectomy in the majority of the cases 12 .…”

Section: Discussionmentioning

confidence: 99%

Metastatic low‐grade endometrial stromal sarcoma after 24 years: A case report and review of recent molecular genetics

Mindiola‐Romero

Dillon

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

Low‐grade endometrial stromal sarcoma (LGESS) is a rare malignant uterine tumor with the potential to metastasize years after the primary resection. There is a broad differential diagnosis for endometrial stromal sarcomas (ESS), including both benign and malignant entities. Herein, we present the case of a 64‐year‐old female with metastatic LGESS to the lung, diagnosed by cytology, 24 years after her initial presentation. This report discusses the cytomorphologic and histopathologic characteristics, and ancillary studies including immunohistochemical stains and recent advances in molecular diagnostics of ESS. Accurate diagnosis of spindle cell lesions in the lung can be challenging. As such, this case highlights the instrumental role of ancillary testing and molecular diagnostics to achieve a more definitive diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Metastatic low‐grade endometrial stromal sarcoma after 24 years: A case report and review of recent molecular genetics

Mindiola‐Romero

Dillon

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…Uterine sarcoma (US) describes a group of rare malignant tumors arising from the uterine musculature or the connective tissue [1]. US represents approximately 1% of all female genital tract malignancies and 3-9% of uterine cancers [2,3].…”

Section: Introductionmentioning

confidence: 99%

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

Sardi

Muñoz‐Zuluaga

Sittig

et al. 2018

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessagePeritoneal sarcomatosis from uterine sarcoma is a rare disease with no effective treatment and poor prognosis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has successful results in peritoneal carcinomatosis from gastrointestinal/gynecological origins. We show that CRS/HIPEC is safe, feasible, and may benefit selected patients with peritoneal sarcomatosis from uterine sarcoma.

show abstract

“…Unfortunately, there exist no effective diagnostic techniques for identifying patients with uLMS. Even modern imaging scans using ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) fail to detect uLMS-specific signs (2). Consequently, uLMS is frequently discovered incidentally on histopathological analysis following hysterectomy.…”

mentioning

confidence: 99%

“…Due to the aggressive clinical course of uLMS, patients have poor prognosis with early hematogenous spread and development of lung metastases within 2 years after primary therapy (2). Furthermore, the metastatic recurrence rate even in patients with localized early stage uLMS exceeds 50% according to the International Federation of Gynecology and Obstetrics (FIGO) (3).…”

mentioning

confidence: 99%

“…Treatment of uLMS patients still remains challenging. Since response to chemo-and radiation therapy exhibits little, if any, effect, complete surgical resection represents the best and potentially curative treatment for localized uLMS (2,4). Only a few prognostic factors (age, tumor size, early stage) have been evaluated for uLMS therapy, while molecular biomarkers are completely missing (1,5).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma

Stope

Cernat

Kaul

et al. 2018

View full text Add to dashboard Cite

show abstract

Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015)

Cited by 8 publications

References 0 publications

Metastatic low‐grade endometrial stromal sarcoma after 24 years: A case report and review of recent molecular genetics

Metastatic low‐grade endometrial stromal sarcoma after 24 years: A case report and review of recent molecular genetics

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma

Contact Info

Product

Resources

About